Fosamax and Osteonecrosis of the Jaw: Legal Considerations for New Jersey Patients

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Risk Awareness

For decades, general health and science information has served as the foundation for public understanding of medical conditions and treatment options. This legacy context emphasizes broad awareness of wellness, disease prevention, and the importance of informed patient decision-making. Within this framework, discussions of pharmaceutical interventions have historically focused on benefits and common side effects, providing a baseline for patient education. As the field of health communication has evolved, there has been a growing recognition of the need to address specific, long-term risks associated with widely prescribed medications. One such area of concern involves bisphosphonate drugs, which have been linked to rare but serious adverse events in certain patient populations. This shift from general health guidance to targeted risk awareness naturally leads to a more focused examination of occupational and environmental exposures. In particular, the transition from broad health literacy to specialized legal and medical scrutiny highlights the importance of understanding how prolonged use of certain medications may intersect with individual patient circumstances. This pivot acknowledges that while general health information remains valuable, there are instances where detailed, context-specific knowledge becomes critical for both patients and professionals.

Understanding Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Medical Evidence and Risk Context

The time to onset of symptoms of ONJ after starting Fosamax has been reported to vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The incidence of ONJ is considered rare (https://pubmed.ncbi.nlm.nih.gov/42046648/). From a medical risk perspective, the adequacy of warnings regarding Fosamax and ONJ is a key consideration. The prescribing information for Fosamax includes a warning about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also identifies known risk factors and suggests that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the warning does not specify a precise timeline for risk or provide detailed guidance on monitoring for ONJ in all patients. The clinical presentation of ONJ can include pain, swelling, infection, and exposed bone in the jaw, often following dental procedures. Diagnosis typically involves clinical examination and imaging, such as panoramic radiographs or CT scans, to assess bone changes.

Statute of Limitations for Fosamax Claims in New Jersey

For affected patients in New Jersey, attorney-related considerations involve the statute of limitations for filing a claim related to Fosamax and ONJ. The statute of limitations is a legal time limit within which a lawsuit must be filed. In New Jersey, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. This means that patients who develop ONJ after taking Fosamax must file a claim within two years of becoming aware of their injury and its potential link to the medication. The timeline between exposure to Fosamax and documented harm is variable, as ONJ can occur from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Additionally, the risk of ONJ may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients who have taken Fosamax for several years and later develop ONJ should be aware that the statute of limitations may begin when they first experience symptoms or receive a diagnosis, not necessarily when they stopped taking the medication. In summary, Fosamax is associated with a rare risk of ONJ, with onset varying from days to months after starting the drug. The prescribing information includes warnings about this risk and identifies factors that may increase it, such as invasive dental procedures and longer exposure. Patients in New Jersey who develop ONJ after taking Fosamax should consider consulting an attorney to understand the statute of limitations for their potential claim, which is generally two years from discovery of the injury. The timeline between exposure and harm is variable, and legal advice should be sought promptly to ensure compliance with applicable deadlines.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in New Jersey?

In New Jersey, the statute of limitations for personal injury claims, including those related to pharmaceutical products like Fosamax, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. This means patients must file a claim within two years of becoming aware of their ONJ diagnosis and its potential link to Fosamax.

How long after starting Fosamax can ONJ develop?

The time to onset of ONJ symptoms after starting Fosamax has been reported to vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.